Leddy (@LeddyLLC) on X
Short summary
A tweet thread highlighting a study where chronically stressed adults took 600mg of ashwagandha daily for 60 days, with cortisol falling 27.9% and stress scores dropping 44%. The post is a teaser for a 10-part breakdown, so the details of the study itself aren't in this piece.
- Adults under chronic stress took 600mg of ashwagandha per day for 60 days.
- Cortisol dropped 27.9% and self-reported stress scores fell 44%.
- The thread promises a breakdown of the study, but this post alone gives no sample size, controls, or methodology.
Full summary
The post is a short teaser thread, not a full study writeup. Its core claim: chronically stressed adults who took 600 mg of ashwagandha daily for 60 days saw their cortisol fall 27.9% and their stress scores drop 44%. The author promises a 10-part breakdown but the content here stops at the headline numbers, so the actual study design, sample size, comparison group, and measurement methods aren't in the text. That matters because the two headline figures are the kind of result that can look dramatic in a tweet and shrink considerably once you see the controls.
Those missing details are where to focus before trusting the numbers. A 27.9% cortisol drop could be compared against a placebo group or against the participants' own baseline, and those are very different claims. The 44% stress score reduction depends on which scale was used, such as the Perceived Stress Scale, and whether the reported change was an average or a subset. Several ashwagandha trials, including ones using the KSM-66 root extract and Sensoril formulations, have reported stress and cortisol benefits, but the dose, extract type, and population vary a lot across studies, so the 600 mg figure alone doesn't tell you whether this result generalizes.
If you're saving this to read later, the thing to look for is the full thread or the original paper it's summarizing. Find the trial registration or journal citation, check the sample size and whether there was a placebo arm, and see whether the 27.9% and 44% figures are primary endpoints or secondary findings. Until that's in hand, treat the numbers as a promising lead rather than a settled result.